Literature DB >> 10526580

Dexamethasone enhances CTLA-4 expression during T cell activation.

M Xia1, J Gasser, U Feige.   

Abstract

T cell activation is enhanced by the costimulatory interaction of B7 on antigen-presenting cells and CD28 on T cells, resulting in long-term T cell proliferation, differentiation and production of large amounts of cytokines, such as interleukin (IL)-2. CTLA-4 is a co-stimulation receptor that shares 31% homology with CD28 and binds B7 family members with higher affinity. CTLA-4 is transiently expressed intracellularly and on the cell surface following activation of T cells. We have studied the kinetics of CTLA-4 expression and the effects of dexamethasone on CTLA-4 expression during T cell activation in cultures of mouse spleen cells stimulated by a mixture of immobilized anti-CD3 and anti-CD28 monoclonal antibodies (anti-CD3/CD28 mAb) or concanavalin A (ConA). CTLA-4 expression peaked on day 2 and returned to background levels after 7 days. Dexamethasone was found to potentiate CTLA-4 expression in a dose-dependent manner with an EC50 effective concentration 50%) of about 10(-8) M. In contrast, other immunosuppressive agents, such as rapamycin or cyclosporin A had no or an inhibitory effect on CTLA-4 expression, respectively. Dexamethasone also stimulated CD28 expression, but inhibited IL-2R expression during anti-CD3/CD28 mAb-induced mouse splenic T cell activation. Western blot analyses of lysates of activated mouse T cells showed that dexamethasone increased CTLA-4 protein levels twofold during anti-CD3/CD28 mAb-induced activation. Dexamethasone also enhanced CTLA-4 messenger RNA twofold as quantified by ribonuclease protection assay. The effects of dexamethasone on CTLA-4 expression were glucocorticoid-specific and completely inhibited by the glucocorticoid receptor antagonist mifepristone (RU486), indicating that the effect of dexamethasone on CTLA-4 expression is mediated through the glucocorticoid receptor. In conclusion, the immunosuppressive agent dexamethasone actually stimulates CTLA-4 expression, which is involved in downregulation of T cell activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10526580     DOI: 10.1007/s000180050403

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  17 in total

Review 1.  Peritoneal damage: the inflammatory response and clinical implications of the neuro-immuno-humoral axis.

Authors:  Tarik Sammour; Arman Kahokehr; Mattias Soop; Andrew G Hill
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 2.  The Role of Checkpoint Inhibitors in Glioblastoma.

Authors:  Kunal Desai; Anne Hubben; Manmeet Ahluwalia
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

Review 3.  Glucocorticoids in T cell development, differentiation and function.

Authors:  Matthew D Taves; Jonathan D Ashwell
Journal:  Nat Rev Immunol       Date:  2020-11-04       Impact factor: 53.106

4.  Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells.

Authors:  Natsumi Maeda; Takumi Maruhashi; Daisuke Sugiura; Kenji Shimizu; Il-Mi Okazaki; Taku Okazaki
Journal:  J Biol Chem       Date:  2019-11-13       Impact factor: 5.157

Review 5.  The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.

Authors:  Andrew S Luksik; Russell Maxwell; Tomas Garzon-Muvdi; Michael Lim
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

6.  Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis.

Authors:  K Tjandra; T Le; M G Swain
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

7.  Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis?

Authors:  Gabriel Cara-Fuentes; Clive H Wasserfall; Heiman Wang; Richard J Johnson; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2014-07-14       Impact factor: 3.714

Review 8.  Immune tolerance induction by integrating innate and adaptive immune regulators.

Authors:  Jun Suzuki; Camillo Ricordi; Zhibin Chen
Journal:  Cell Transplant       Date:  2009-11-16       Impact factor: 4.064

Review 9.  Glucocorticoids and immune checkpoint inhibitors in glioblastoma.

Authors:  William J Kelly; Mark R Gilbert
Journal:  J Neurooncol       Date:  2020-02-27       Impact factor: 4.130

10.  Role of CD28/B7 costimulation and IL-12/IL-10 interaction in the radiation-induced immune changes.

Authors:  S Z Liu; S Z Jin; X D Liu; Y M Sun
Journal:  BMC Immunol       Date:  2001-08-07       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.